Stutterheim J, van der Waarden R, de Groot-Kruseman H, Sonneveld E, de Haas V, Dandis R
Leukemia. 2024; 38(11):2376-2381.
PMID: 39256602
PMC: 11518975.
DOI: 10.1038/s41375-024-02386-5.
Kotrova M, Fronkova E, Svaton M, Drandi D, Schon F, Hoogeveen P
Leukemia. 2024; 38(7):1617-1620.
PMID: 38760480
PMC: 11216996.
DOI: 10.1038/s41375-024-02265-z.
van der Velden V, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D
Leukemia. 2024; 38(6):1315-1322.
PMID: 38744919
PMC: 11147754.
DOI: 10.1038/s41375-024-02272-0.
Schilhabel A, Szczepanowski M, van Gastel-Mol E, Schillalies J, Ray J, Kim D
Front Oncol. 2023; 12:1111209.
PMID: 36727082
PMC: 9885152.
DOI: 10.3389/fonc.2022.1111209.
Fronkova E, Svaton M, Trka J
Methods Mol Biol. 2022; 2453:91-99.
PMID: 35622322
PMC: 9761552.
DOI: 10.1007/978-1-0716-2115-8_6.
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods.
Kotrova M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K
Blood Adv. 2022; 6(10):3006-3010.
PMID: 35026836
PMC: 9131918.
DOI: 10.1182/bloodadvances.2021006727.
Clinical Implications of Minimal Residual Disease Detection in Infants With -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
Stutterheim J, van der Sluis I, De Lorenzo P, Alten J, Ancliffe P, Attarbaschi A
J Clin Oncol. 2021; 39(6):652-662.
PMID: 33405950
PMC: 8196086.
DOI: 10.1200/JCO.20.02333.
Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?.
Balduzzi A
Bone Marrow Transplant. 2017; 52(7):952-954.
PMID: 28581473
DOI: 10.1038/bmt.2017.104.
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?.
Kotrova M, Trka J, Kneba M, Bruggemann M
Mol Diagn Ther. 2017; 21(5):481-492.
PMID: 28452038
DOI: 10.1007/s40291-017-0277-9.
Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.
Kotrova M, van der Velden V, van Dongen J, Formankova R, Sedlacek P, Bruggemann M
Bone Marrow Transplant. 2017; 52(7):962-968.
PMID: 28244980
DOI: 10.1038/bmt.2017.16.
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling A, Gaipa G, Bartels M
Blood. 2016; 129(3):347-357.
PMID: 27903527
PMC: 5291958.
DOI: 10.1182/blood-2016-07-726307.
[The relationship between WT1 expression level and prognosis in patients of acute T lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].
Zhang B, Zhao X, Qin Y, Wang Y, Yan C, Xu L
Zhonghua Xue Ye Xue Za Zhi. 2015; 36(8):642-6.
PMID: 26462631
PMC: 7348268.
DOI: 10.3760/cma.j.issn.0253-2727.2015.08.003.
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
van Dongen J, van der Velden V, Bruggemann M, Orfao A
Blood. 2015; 125(26):3996-4009.
PMID: 25999452
PMC: 4490298.
DOI: 10.1182/blood-2015-03-580027.
Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.
Bai J, He A, Huang C, Yang J, Zhang W, Wang J
Proteome Sci. 2014; 12(1):49.
PMID: 25317080
PMC: 4195909.
DOI: 10.1186/s12953-014-0049-y.
Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.
Salari F, Shahjahani M, Shahrabi S, Saki N
Med Oncol. 2014; 31(11):266.
PMID: 25287907
DOI: 10.1007/s12032-014-0266-3.
Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D, Emerson R, Sherwood A, Loh M, Angiolillo A, Howie B
Clin Cancer Res. 2014; 20(17):4540-8.
PMID: 24970842
PMC: 5142743.
DOI: 10.1158/1078-0432.CCR-13-3231.
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
Bene M, Kaeda J
Haematologica. 2009; 94(8):1135-50.
PMID: 19586938
PMC: 2719036.
DOI: 10.3324/haematol.2008.004267.
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.
Morley A, Latham S, Brisco M, Sykes P, Sutton R, Hughes E
J Mol Diagn. 2009; 11(3):201-10.
PMID: 19324989
PMC: 2671337.
DOI: 10.2353/jmoldx.2009.080048.
